# Artax Biopharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/artax-biopharma

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: http://www.artaxbiopharma.com
- Total disclosed funding: $29M
- Latest round: Series B (May 11, 2022)
- Investors on record: 5

## About

Artax Biopharma, Inc. develops innovative immunomodulatory therapies aimed at treating autoimmune diseases without immunosuppression, focusing on maintaining healthy immune system responses while mitigating risks associated with autoimmune disorders.Founded in 2013 and headquartered in Cambridge, US, Artax Biopharma, Inc. is dedicated to the development of therapies for autoimmune diseases. The company operates independently, with no known subsidiaries or parent companies. The CEO and founder, Damia Tormo, has a history of founding and leading companies in the biopharmaceutical sector. As of August 2024, Artax completed its SERIES B funding, raising a total of USD 26.00 mn from investors including Eli Lilly & Company and Advent Life Sciences, marking its most recent deal on August 6, 2024. This brings the total amount raised by the company to USD 26.00 mn, with a current valuation of USD 51.35 mn.Artax Biopharma specializes in developing immunomodulatory therapies, with AX-158 as its primary product. This oral small molecule acts as a Nck modulator, inhibiting Nck binding to the T cell receptor to prevent inappropriate T cell activation by self-antigens. AX-158 has shown promising results in Phase 2a clinical trials for psoriasis and is anticipated to enter Phase 2 trials for atopic dermatitis and other autoimmune conditions in 2025. The company aims to expand its reach in North America and Europe, addressing the needs of patients affected by autoimmune diseases, which impact approximately 1 in 10 individuals globally.Artax Biopharma generates revenue through partnerships and clinical trial engagements with healthcare providers and pharmaceutical companies. The company's revenue structure primarily relies on collaborative agreements for the development and commercialization of AX-158 and other products in its pipeline, with revenue derived from milestone payments and potential royalties as products advance through development phases. The flagship product AX-158 is on track for further clinical validation, with the aim of securing partnerships that facilitate broader market access for treatments of autoimmune conditions.Artax Biopharma plans to leverage the recent funding of USD 8 mn raised in August 2024 to advance its clinical trials and expand its product pipeline. The company is focused on launching AX-158 for additional autoimmune conditions and aims to initiate further trials in 2025. Additionally, Artax is targeting growth in North American and European markets, enhancing its partnerships and collaborations to drive revenue generation and increase accessibility to its innovative therapies.

## Funding rounds

- Series B, May 11, 2022, $26M — Eli Lilly & Company, Advent Life Sciences, Columbus Venture Partners, Sound Bioventures
- Series B, Jun 4, 2020 — Columbus Venture Partners
- Series B, Jul 29, 2015, $3M — Pappas Capital, Advent Life Sciences

## Investors

- Pappas Capital (https://capitalatlas.ai/funds/pappas-capital) — Series B
- Advent Life Sciences (https://capitalatlas.ai/funds/advent-life-sciences) — Series B
- Columbus Venture Partners (https://capitalatlas.ai/funds/columbus-venture-partners) — Series B
- Eli Lilly & Company — Series B
- Sound Bioventures (https://capitalatlas.ai/funds/sound-bioventures) — Series B